Cefepime Induced Encephalopathy in a Non-dialysis Dependent Chronic Kidney Disease Patient: A Case Report

Authors

  • Giritharan Muniandy Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Malaysia
  • Lydia Kamaruzaman Nephrology Unit, Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Malaysia
  • Tan Hui Jan Neurology Unit, Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Malaysia
  • Rozita Mohd Nephrology Unit, Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Malaysia
  • Mariamutu Theepa Neesam Nephrology Unit, Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Malaysia
  • Ken Fong Voon Nephrology Unit, Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Malaysia
  • Beng Pau Kiew Department of Pharmacy, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia, Malaysia
  • Ruslinda Mustafar Nephrology Unit, Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Malaysia

Keywords:

Cefepime, encephalopathy, chronic kidney disease

Abstract

Cefepime is a frequently used fourth-generation cephalosporin antibiotic for a wide variety of infections. Toxic levels of this drug can cause neurological complications. The most common neurological adverse event of cefepime is headache and lightheadedness. Here, we presented a case of cefepime induced encephalopathy in a 57-year-old female patient with acute on chronic kidney disease. With an accurate diagnosis that requires a high index of clinical suspicion, prompt management was instituted. She had full resolution of symptoms following discontinuation of the medication and also emergent dialysis.

References

Burgess SV, Mabasa VH, Chow I, Ensom MH. Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review. Ann Pharmacother. 2015;49(3):311-22.

Bazan JA, Martin SI, Kaye KM. Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime. The Medical Clinics of North America. 2011;95(4):743-60, viii.

Wong KM, Chan WK, Chan YH, Li CS. Cefepime-related neurotoxicity in a haemodialysis patient. Nephrol Dial Transplant. 1999;14(9):2265-6.

Neu HC. Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am J Med. 1996;100(6A):68S-75S.

Durand-Maugard C, Lemaire-Hurtel AS, Gras-Champel V, et al. Blood and CSF monitoring of cefepime-induced neurotoxicity: nine case reports. J Antimicrobial Chemother. 2012;67(5):1297-9.

FDA Drug Safety Communication: Cefepime and risk of seizure in patients not receiving dosage adjustments for kidney impairment. 2012.

Eggers V, Fugener K, Hein OV, et al. Antibiotic- mediated release of tumour necrosis factor alpha and norharman in patients with hospital-acquired pneumonia and septic encephalopathy. Intensive Care Medicine. 2004;30(8):1544-51.

Desarro A, Ammendola D, Zappala M, Grasso S, Desarro GB. Relationship between structure and convulsant properties of some beta-lactam antibiotics following intracerebroventricular microinjection in rats. Antimicrob Agents Ch. 1995;39(1):232-7.

Jallon P, Fankhauser L, Du Pasquier R, et al. Severe but reversible encephalopathy associated with cefepime. Neurophysiologie clinique - Clinical neurophysiology. 2000;30(6):383-6.

Martinez-Rodriguez JE, Barriga FJ, Santamaria J, et al. Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. Am J Med. 2001;111(2):115-9.

Grill MF, Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother. 2008;42(12):1843-50.

Fugate JE, Kalimullah EA, Hocker SE, Clark SL, Wijdicks EF, Rabinstein AA. Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy. Crit Care. 2013;17(6):R264.

Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrobial Chemother. 2006;57(2):176-89.

Song JC. Cefepime: FDA drug safety communication on non-convulsive status epilepticus risk. Infectious Disease (alert). 2012.

Lamoth F, Buclin T, Pascual A, et al. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother. 2010;54(10):4360-7.

Huwyler T, Lenggenhager L, Abbas M, et al. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study. Clinical Microbiology Infection. 2017;23(7):454-9.

Sonck J, Laureys G, Verbeelen D. The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol Dial Transplant. 2008;23(3):966-70.

Chatellier D, Jourdain M, Mangalaboyi J, et al. Cefepime- induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure. Intensive Care Medicine. 2002;28(2):214-7.

Payne LE, Gagnon DJ, Riker RR, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017;21(1):276.

Gangireddy VG, Mitchell LC, Coleman T. Cefepime neurotoxicity despite renal adjusted dosing. Scandinavian J Infect Dis. 2011;43(10):827-9.

Downloads

Published

2023-03-31

How to Cite

Muniandy, G., Kamaruzaman, L., Jan, T. H., Mohd, R., Neesam, M. T., Fong Voon, K., Pau Kiew, B., & Mustafar, R. (2023). Cefepime Induced Encephalopathy in a Non-dialysis Dependent Chronic Kidney Disease Patient: A Case Report. Acta Medica Indonesiana, 55(1), 78. Retrieved from https://www.actamedindones.org/index.php/ijim/article/view/1367

Issue

Vol. 55 No. 1 (2023): Acta Medica Indonesiana

Section

CASE REPORT

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.